摘要硼替佐米可通过多种机制可逆地抑制蛋白酶体发挥其抗骨髓瘤作用，是我国目前治疗多发性骨髓瘤的一线药物。硼替佐米诱发的周围神经病变（bortezomib-induced peripheral neuropathy，BIPN）是多发性骨髓瘤患者治疗过程中最常见、最令人担忧的剂量限制性不良反应之一，可严重影响患者的生活质量，导致减药甚至停药。如何减少或预防BIPN的发生是多发性骨髓瘤治疗过程中的难题。基于此，该研究从施万细胞、神经元、星形胶质细胞等方面综述了BIPN的发病机制。

abstractsBortezomib exerts its anti-myeloma effect by reversibly inhibiting the proteasome through various mechanisms, and it is currently the first-line drug for the treatment of multiple myeloma in China. Bortezomib-induced peripheral neuropathy is one of the most common dose-limiting adverse reactions in the treatment process, which seriously affects the quality of life of patients, leading to dose reduction or even drug withdrawal. How to reduce or prevent Bortezomib-induced peripheral neuropathy remains a challenging problem in the treatment of multiple myeloma. Based on this, this article reviews the pathogenesis of Bortezomib-induced peripheral neuropathy from the perspectives of Schwann cells, neurons, astrocytes, macrophages, and other aspects.